Mark A. Moyad, MD, MPH, presented “Diet Only and Prostate Cancer ” during the 31st International Prostate Cancer Update in July 2021 in Snowbird, Utah.
How to cite: Moyad, Mark A. “Diet Only and Prostate Cancer.” July 2021. Accessed Dec 2024. https://dev.grandroundsinurology.com/diet-only-and-prostate-cancer/
Diet Only and Prostate Cancer – Summary
Mark A. Moyad, MD, MPH, Jenkins/Pokempner Director of Preventive/Complementary and Alternative Medicine (CAM) in the University of Michigan Department of Urology, reviews several trials showing the impact of dieting to lose weight on cancer and cancer recurrence, focusing particularly on prostate cancer. He begins with a discussion of the WINS and WHEL trials on dietary changes and breast cancer which, together, found that improving the quality of a diet does not appear to have a profound impact on cancer or recurrence, but that while dieting with a focus on weight loss reduces recurrence rates and establishes a number needed to treat (NNT) of 38. Dr. Moyad continues with preliminary data from the Success-C trial, a study with the goal of using caloric reduction and exercise to reduce weight and is showing that those who adhere to the lifestyle changes have significantly improved rates of disease-free survival. He then looks at the POUNDS LOST trial, whose results suggest that, regardless of the weight-loss process, if weight loss occurs then health benefits can be reached. Dr. Moyad also discusses the CALERIE and MEAL trials. The former study had patients cut back calories by 13% on average and showed that slow methodical weight-loss creates heart-healthy metabolic and numeric changes. The latter had active surveillance participants significantly increase their vegetable intake but has not currently found any remarkable differences between the control and intervention groups. He also discusses the latest impressive vegan randomized study, which demonstrated dramatic weight loss of 14 lbs over 16 weeks utilizing a practically unrecognized caloric reduction strategy. He summarizes the results of over 85 studies on excess alcohol and adipose tissue which support the idea that both are carcinogens and are shown to reduce the efficacy of some drugs. Dr. Moyad also observes that data on lycopene shows that increased fruit and vegetable intake is supportive of overall heart health, how recent research shows no clear cause and effect link between cancer and vitamin D or omega 3s, and how the MANSMED trial shows the benefit of using metformin in addition to standard-of-care therapy. He concludes by observing that heart-healthy calorie restriction programs that encourage adherence, happiness, and healthy outcomes are good for managing prostate cancer, and by briefly discussing the potential of semaglutide injections to help some patients lose weight.
About The 31st Annual International Prostate Cancer Update:
The International Prostate Cancer Update (IPCU), founded in 1990, is a multi-day CME conference focused on prostate cancer treatment updates with expert, international faculty. It is led by expert physicians and is designed for urologists, medical oncologists, radiation oncologists, and other healthcare professionals involved in the diagnosis and treatment of prostate cancer. Dr. Moyad delivered this educational activity during the 31st iteration of the meeting in July 2021 in Snowbird, Utah.
ABOUT THE AUTHOR
Dr. Moyad is the Jenkins/Pokempner Director of Preventive/Complementary and Alternative Medicine (CAM) at the University of Michigan Medical Center in the Department of Urology. He occupies an endowed position, which was originally created and funded entirely by the patients he has helped over the past 25+ years. This was the first endowment of its kind created for a physician at a major medical center in the US. Dr. Moyad has always considered himself to be, first and foremost, a physician public health educator. Dr. Moyad believes in the power of lifestyle changes to improve overall mental, physical, and spiritual wellness, and in their potential ability to keep pill counts and dosages to a minimum, while also enhancing the impact of conventional treatments when needed. This has been the focus of his research and lectures his entire career. Dr. Moyad received his medical education from the University of South Florida College of Public Health and the Wayne State University School of Medicine. He is the primary author of over 150 published medical journal articles on the subject of lifestyle changes and supplements, the past Editor-in-Chief of the medical journal Seminars in Preventive & Alternative Medicine, and has given 1000s of lectures around the world to public and health care professionals in virtually every medical specialty and major medical center. Dr. Moyad is the author or co-author of 15 academic and consumer books, including the Integrative Medicine Clinical/Teaching Guidebooks, the Promoting Wellness series for patients, and his public bestseller The Supplement Handbook. He is honored to be the moderator of one of the largest patient conferences held twice a year in Los Angeles, California, and has provided monthly educational clinical research updates for the last 15+ years to health care professionals and national patient advocacy groups. He has been a consultant and/or interviewed for most major magazines, websites, radio and television shows devoted to health in the US, and appears regularly on a variety of programs.
A. Karim Kader, MD, PhD, is a board-certified urologist who specializes in screening, detecting, treating and preventing prostate cancer. As a Professor in the Department of Urology and Director of Urologic Oncology at the University of California, San Diego, Dr. Kader instructs medical students, residents and fellows at UC San Diego School of Medicine. His current research interests include genetic markers to assess risk and predict outcomes in urologic cancer. In addition, he examines the impact of augmented reality and enhanced imaging techniques for education and improved surgical outcomes. Dr. Kader completed a Fellowship in Urologic Oncology at the University of Texas MD Anderson Cancer Center in Houston and a Residency in Urology at the University of Toronto in Ontario, Canada. He earned his medical degree and doctoral degree from the University of British Columbia in Vancouver, British Columbia. Dr. Kader is nationally recognized for his expertise in performing robot-assisted radical cystectomy and urinary diversion for patients with bladder cancer. He holds several patents for genetic discoveries focused on the early detection and prevention of prostate cancer in addition to device patents for prostate cancer treatment. He is the principal investigator in numerous clinical research projects and has published extensively.
